Lawrence M. Lichtenstein

Lawrence M. Lichtenstein's AcademicInfluence.com Rankings

Philosophy

#2240

World Rank

#3877

Historical Rank

Ontology

World Rank

#12

Historical Rank

Logic

#498

World Rank

#920

Historical Rank

philosophy Degrees

Lawrence M. Lichtenstein

Biology

#2496

World Rank

#3950

Historical Rank

Immunology

#88

World Rank

#94

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Lawrence M. Lichtenstein's Degrees

PhD Immunology Stanford University
Doctorate Medicine Stanford University

Why Is Lawrence M. Lichtenstein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence M. Lichtenstein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Modulation of inflammation and immunity by cyclic AMP. (1974) (891)
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. (1997) (794)
Inflammatory mediators in late antigen-induced rhinitis. (1985) (715)
A controlled trial of immunotherapy in insect hypersensitivity. (1978) (612)
STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA. IX. HISTAMINE RELEASE FROM HUMAN LEUKOCYTES BY RAGWEED POLLEN ANTIGEN. (1964) (597)
Mediator release after nasal airway challenge with allergen. (2015) (504)
Histamie Release in vitro: Inhibition by Catecholamines and Methylxanthines (1968) (432)
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. (2000) (404)
IL-13 expression at the sites of allergen challenge in patients with asthma. (1995) (391)
Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. (1984) (382)
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. (1972) (378)
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. (1991) (366)
Treatment of cat allergy with T-cell reactive peptides. (1996) (357)
Physiologic manifestations of human anaphylaxis. (1980) (335)
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. (1973) (335)
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. (1983) (323)
The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. (1992) (315)
Immunological aspects of allergic asthma. (1994) (314)
Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. (1988) (305)
Generation of leukotrienes by purified human lung mast cells. (1982) (292)
Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. (1994) (287)
The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment. (1988) (280)
Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. (1995) (274)
Kinins are generated during experimental rhinovirus colds. (1988) (273)
IgE receptors on human basophils. Relationship to serum IgE concentration. (1978) (258)
Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. (1990) (257)
Epidemiology of insect venom sensitivity. (1989) (255)
Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. (1987) (254)
Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. (1989) (252)
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. (1985) (245)
Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. (1987) (245)
Arachidonic acid metabolism in purified human lung mast cells. (1984) (234)
CURRENT CONCEPTS : ANAPHYLAXIS (1991) (231)
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. (1975) (229)
Human lung mast cells: purification and characterization. (1982) (224)
Measurement of IgE on human basophils: relation to serum IgE and anti-IgE-induced histamine release. (1977) (223)
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. (2000) (222)
Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. (1983) (217)
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. (1972) (216)
Identification of basophil granulocytes as a site of allergic histamine release. (1972) (216)
Platelet activation during antigen-induced airway reactions in asthmatic subjects. (1981) (214)
Asthma: physiology, immunopharmacology, and treatment (1973) (212)
Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. (1989) (212)
A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. (1968) (209)
The value of immunotherapy with venom in children with allergy to insect stings. (1990) (205)
Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. (1988) (205)
Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. (1985) (203)
Down-Regulation of Human Basophil IgE and FCεRIα Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo (1999) (199)
Isolation and characterization of allergens from ragweed pollen. IV. (1964) (196)
Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. (1986) (195)
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. (1983) (194)
Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. (1984) (191)
In vitro studies of antigen-induced bronchospasm: effect of antihistamine and SRS-A antagonist on response of sensitized guinea pig and human airways to antigen. (1979) (190)
Diagnostic tests in ragweed hay fever. A comparison of direct skin tests, IgE antibody measurements, and basophil histamine release. (1973) (189)
Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. (1982) (184)
Insect allergy: the state of the art. (1979) (182)
Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. (1987) (178)
Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos. (1968) (176)
A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. (1971) (174)
Selective display of histamine receptors on lymphocytes. (1977) (168)
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. (1972) (167)
IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. (1994) (167)
Regimens of Hymenoptera venom immunotherapy. (1980) (167)
Regulation of human basophil and lung mast cell function by cyclic adenosine monophosphate. (1988) (165)
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. (1968) (164)
The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. (1975) (162)
Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. (1994) (159)
Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. (1990) (158)
In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization. (1966) (157)
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. (1991) (157)
Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. (1987) (156)
Protein allergens of white-faced hornet, yellow hornet, and yellow jacket venoms. (1978) (154)
Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. (1979) (153)
A comparison of the osmotic activation of basophils and human lung mast cells. (2015) (153)
Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. (1970) (152)
Allergens of honey bee venom. (1976) (151)
Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. (1969) (149)
IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. (1976) (148)
Properties of a subpopulation of T cells bearing histamine receptors. (1975) (147)
Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. (1991) (147)
Insect sting allergy with negative venom skin test responses. (2001) (146)
Characterization of inflammatory mediator release from purified human lung mast cells. (1986) (143)
Hyperosmolar triggering of histamine release from human basophils. (1981) (143)
Discontinuing venom immunotherapy: outcome after five years. (1996) (142)
Adenosine potentiates mediator release from human lung mast cells. (1988) (142)
In vitro regulation of FcεRIα expression on human basophils by IgE antibody (1998) (141)
Immunologic and cellular changes accompanying the therapy of pollen allergy. (1971) (141)
Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. (2001) (139)
Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. (1989) (139)
Isolation and characterization of human intestinal mucosal mast cells. (1985) (135)
Survey of patients after discontinuing venom immunotherapy. (2000) (135)
Defective histamine release in chronic urticaria. (1976) (135)
Recombinant IL-3 induces histamine release from human basophils. (1989) (133)
Influx of kininogens into nasal secretions after antigen challenge of allergic individuals. (1985) (133)
Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. (1992) (133)
Mediator release after nasal airway challenge with allergen. (1983) (130)
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. (1973) (129)
Allergy to insect stings. I. Diagnosis of IgE-mediated hymenoptera sensitivity by venom-induced histamine release. (1974) (129)
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. (1971) (129)
Diagnosis of allergy to stinging insects by skin testing with Hymenoptera venoms. (1976) (126)
Dose dependence of Hymenoptera venom immunotherapy. (1981) (126)
The role of cyclic AMP in the cytolytic activity of lymphocytes. (1971) (125)
Human basophils: mediator release and cytokine production. (2001) (125)
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. (1974) (125)
Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. (1994) (125)
Discontinuing venom immunotherapy: extended observations. (1998) (124)
Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. (1982) (122)
Natural history of Hymenoptera venom sensitivity in adults. (1997) (121)
Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. (1990) (120)
Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. (1976) (119)
Role of human basophils and mast cells in the pathogenesis of allergic diseases. (1985) (118)
Characterization of a specific adenosine receptor on human lymphocytes. (1978) (117)
The potency and antigen E content of commercially prepared ragweed extracts. (1970) (117)
Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells (1988) (117)
Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. (1991) (117)
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. (1971) (117)
Identification of histamine releasing factor(s) in the late phase of cutaneous IgE-mediated reactions. (1986) (116)
Outcomes of allergy to insect stings in children, with and without venom immunotherapy. (2004) (113)
Effects of peptide therapy on ex vivo T-cell responses. (1998) (112)
The role of ragweed pollen in autumnal asthma. (1977) (111)
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. (1973) (111)
Ultrastructural immunogold localization of prostaglandin endoperoxide synthase (cyclooxygenase) to non-membrane-bound cytoplasmic lipid bodies in human lung mast cells, alveolar macrophages, type II pneumocytes, and neutrophils. (1992) (110)
Routine use of penicillin skin testing on an inpatient service. (1971) (110)
Eosinophil transendothelial migration induced by cytokines. II. Potentiation of eosinophil transendothelial migration by eosinophil-active cytokines. (1994) (109)
Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. (1979) (108)
Recombinant histamine-releasing factor enhances IgE-dependent IL-4 and IL-13 secretion by human basophils. (1997) (108)
Responses to ragweed-pollen nasal challenge before and after immunotherapy. (1989) (107)
Human lung macrophage-derived histamine-releasing activity is due to IgE-dependent factors. (1986) (107)
Relationship between the early, late, and rechallenge reaction to nasal challenge with antigen: observations on the role of inflammatory mediators and cells. (1990) (107)
Heterogeneity of human mast cells. (1983) (106)
Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions. (1986) (106)
Inhibition of basophil histamine release by anti-inflammatory steroids. II. Studies on the mechanism of action. (1982) (104)
In vivo release of inflammatory mediators by hyperosmolar solutions. (1988) (104)
Comparative studies of human basophils and mast cells. (1983) (103)
Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. (1997) (102)
Basophil "releasability" in patients with asthma. (1980) (102)
The clinical and immunologic specificity of immunotherapy. (1978) (101)
A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. (1982) (101)
A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. (1980) (101)
Human lung macrophages induce histamine release from basophils and mast cells. (1985) (101)
Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. (1998) (99)
Interleukin-1 is released at sites of human cutaneous allergic reactions. (1990) (99)
Studies on the allergic and nonallergic nasal inflammation. (1988) (98)
IL-3 augments adhesiveness for endothelium and CD11b expression in human basophils but not neutrophils. (1990) (98)
Basophil histamine release induced by a substance from stimulated human platelets. (1986) (97)
Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in asthmatic patients. (1985) (97)
The purification of human basophils. (1980) (97)
A prospective study of the natural history of large local reactions after Hymenoptera stings in children. (1984) (96)
Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. (1981) (96)
Human uterine mast cells. Isolation, purification, characterization, ultrastructure, and pharmacology. (1991) (95)
Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. I. Characterization of the response. (1981) (94)
Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. (1989) (94)
Effects of passive antibody in bee venom anaphylaxis. (1978) (93)
Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions. (1992) (93)
Lipoxygenase products modulate histamine release in human basophils (1981) (93)
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. (1973) (93)
Functional heterogeneity of human mast cells from different anatomic sites: in vitro responses to morphine sulfate. (1987) (92)
Observations on the pathogenesis of nasal priming. (1989) (92)
Successful parenteral desensitization to paclitaxel. (1996) (91)
Histamine-releasing factors and IgE heterogeneity. (1988) (91)
An immunoglobulin E-dependent recombinant histamine-releasing factor induces interleukin-4 secretion from human basophils (1996) (90)
Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human. (1990) (90)
The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. (1980) (90)
A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. (1980) (90)
Adenosine receptor on human basophils: modulation of histamine release. (1979) (87)
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. (1976) (86)
Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. (1994) (85)
Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects. (2001) (84)
Cyclic AMP, Cell Growth, and the Immune Response (1974) (84)
Epidemiologic study of insect allergy in children. II. Effect of accidental stings in allergic children. (1983) (83)
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. (1972) (83)
Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation (1984) (83)
Immunoglobulin E-mediated degranulation of isolated human lung mast cells. (1985) (82)
Preliminary identification and role of phosphodiesterase isozymes in human basophils. (1992) (82)
Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. (1992) (81)
A double-blind study of the discontinuation of ragweed immunotherapy. (1997) (81)
Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. (1989) (80)
Measurement of IgG-blocking antibodies: development and application of a radioimmunoassay. (1976) (80)
Upregulation of FcϵRI on human basophils by IgE antibody is mediated by interaction of IgE with FcϵRI (1999) (80)
The role of the basophil in allergic inflammation (1995) (79)
Trials of alum-precipitated pollen extracts in the treatment of hay fever. (1972) (78)
Basophil and mast cell degranulation: ultrastructural analysis of mechanisms of mediator release. (1983) (78)
Cyclic AMP metabolism in asthma: studies with leukocytes and lymphocytes. (1974) (78)
Antigen-specific desensitization of human basophils. (1979) (78)
Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. (1981) (78)
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. (1992) (77)
Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. (1982) (77)
Differential Release of Mediators From Human Basophils: Differences in Arachidonic Acid Metabolism Following Activation by Unrelated Stimuli (1989) (76)
Induction of histamine secretion by polycations. (1980) (76)
Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. (1999) (76)
Suppression of late-phase skin reactions by immunotherapy with ragweed extract. (1985) (76)
In vitro reversed anaphylaxis: characteristics of anti-IgE mediated histamine release. (1970) (76)
In vitro studies of human reaginic allergy. (1968) (74)
Recombinant Allergens with Reduced Allergenicity but Retaining Immunogenicity of the Natural Allergens: Hybrids of Yellow Jacket and Paper Wasp Venom Allergen Antigen 5s1 (2001) (73)
Current therapy in allergy, immunology, and rheumatology (1988) (73)
Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. (1996) (72)
Local generation of sulfidopeptide leukotrienes upon nasal provocation with cold, dry air. (1986) (70)
The osmolality of nasal secretions increases when inflammatory mediators are released in response to inhalation of cold, dry air. (1988) (70)
Inhibition of histamine and prostaglandin D2 release from human lung mast cells by ciclosporin A. (1989) (70)
An epidemiologic study of insect allergy in children. I. Characteristics of the disease. (1982) (70)
Studies of antigen binding on human basophils. I. Antigen binding and functional consequences. (1983) (70)
Differential regulation of human basophil and lung mast cell function by adenosine. (1991) (69)
Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. (1997) (69)
IgE-mediated histamine release from human basophils: differences between antigen E- and anti-IgE-induced secretion. (1981) (69)
Allergy to insect stings. IV. Diagnosis by radioallergosorbent test (R.A.S.T.). (1978) (69)
Immunochemical studies of yellowjacket venom proteins. (1983) (68)
The effect of cetirizine on early allergic response (1989) (68)
The effect of azelastine on the early allergic response (1992) (68)
Leukotriene B4 as a mediator of early and late reactions to antigen in humans: the effect of systemic glucocorticoid treatment in vivo. (1989) (67)
Antigen-induced IgE-mediated degranulation of human basophils. (1980) (66)
Nerve growth factor or IL-3 induces more IL-13 production from basophils of allergic subjects than from basophils of nonallergic subjects. (2001) (66)
Studies on the mechanisms of hypersensitivity phenomena. XII. An in vitro study of the reaction between ragweed pollen antigen, allergic human serum and ragweed-sensitive human leukocytes. (1966) (65)
In vivo demonstration of inflammatory mediator release following nasal challenge with antigen. (1983) (64)
Human mast cells synthesize new granules during recovery from degranulation. In vitro studies with mast cells purified from human lungs. (1988) (64)
In vitro histamine release from basophils of asthmatic and atopic individuals in D2O. (1982) (64)
Anaphylactic release of a basophil kallikrein-like activity. I. Purification and characterization. (1979) (64)
The effect of indomethacin on immunologic release of histamine and sulfidopeptide leukotrienes from human bronchus and lung parenchyma. (1987) (63)
Anaphylaxis after contact with a jellyfish. (1985) (63)
Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. (1992) (63)
Diagnosis and treatment of anaphylactic reactions to Hymenoptera stings in children. (1980) (63)
Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. (1981) (63)
Serum IgE level drives basophil and mast cell IgE receptor display. (1997) (62)
Histamine Release Due to Bivalent Penicilloyl Haptens Control by the Number of Cross-Linked IgE Antibodies on the Basophil Plasma Membrane (1978) (62)
Investigative use of bronchoscopy, lavage and bronchial biopsies in asthma and other airways diseases. (1992) (62)
Studies of antigen binding on human basophils. II. Continued expression of antigen-specific IgE during antigen-induced desensitization. (1983) (62)
Comparison of human lung and intestinal mast cells. (1988) (60)
Chapter Ten – Histamine and Immune Responses (1982) (60)
Eosinophil chemotactic factor (ECF). I. Release from polymorphonuclear leukocytes by the calcium ionophore A23187. (1976) (60)
Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. II. Interaction with other stimuli. (1982) (60)
Prospective observations on stopping prolonged venom immunotherapy. (1989) (59)
Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell. (1988) (59)
Physiologic responses and histamine release after nasal antigen challenge. Effect of atropine. (1994) (59)
Studies on the mechanism of lymphocyte-mediated cytolysis. 3. The role of microfilaments and microtubules. (1973) (59)
Degranulation of human basophils: quantitative analysis of histamine release and desensitization, due to a bivalent penicilloyl hapten. (1979) (59)
Diagnostic tests in ragweed-allergic asthma. A comparison of direct skin tests, leukocyte histamine release, and quantitative bronchial challenge. (1974) (58)
Demonstration of inhibition of mediator release from human mast cells by azatadine base. In vivo and in vitro evaluation. (1986) (58)
Human mast cells use conservation and condensation mechanisms during recovery from degranulation. In vitro studies with mast cells purified from human lungs. (1986) (58)
Inhibition of T cell-mediated cytotoxicity by anti-inflammatory steroids. (1984) (57)
Theophylline reduces histamine release during pollen-induced rhinitis. (1986) (57)
IL-4 production by human basophils found in the lung following segmental allergen challenge. (2001) (57)
Morphologic mast cell cycles. (1987) (56)
Generation of leukotriene B4 by human lung fragments and purified human lung mast cells. (1988) (56)
Characterization of human synovial mast cells. (1988) (56)
The Role of Basophils in Asthma a (1991) (56)
Antagonism of antigen-induced contraction of guinea pig and human airways (1977) (56)
Quantitative inhalation bronchial challenge in ragweed hay fevery patients: a comparison with ragweed-allergic asthmatics. (1975) (55)
IgE-mediated anaphylactic degranulation of isolated human skin mast cells. (1991) (54)
Recombinant human IL-1 alpha and -1 beta potentiate IgE-mediated histamine release from human basophils. (1989) (54)
In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. (1998) (54)
An inhibitor of lipoxygenase inhibits histamine release from human basophils. (1980) (53)
Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. (1984) (53)
Clinical and immunologic observations in patients who stop venom immunotherapy. (1986) (52)
Release of leukocyte kallikrein mediated by IgE (1975) (52)
Prolonged maintenance interval in hymenoptera venom immunotherapy. (1981) (52)
Disassociation of the release of histamine and arachidonic acid metabolites from osmotically activated basophils and human lung mast cells. (1990) (51)
Interactions of the complement system with endotoxic lipopolysaccharide: the generation of an anaphylatoxin. (1969) (51)
The effect of a topical tricyclic antihistamine on the response of the nasal mucosa to challenge with cold, dry air and histamine. (1987) (51)
Arachidonic acid metabolites during nasal challenge. (1987) (51)
Hydrocortisone and human lymphocytes: increases in cyclic adenosine 3':5'-monophosphate and potentiation of adenylate cyclase-activating agents. (1980) (51)
Immunotherapy in bee-sting anaphylaxis. Use of honeybee venom. (1975) (50)
Modulation of histamine release from human basophils in vitro by physiological concentrations of zinc. (1981) (50)
Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. (1997) (50)
Induction of histamine release from human skin mast cells by bradykinin analogs. (1989) (50)
The transition from specific to nonspecific desensitization in human basophils. (1981) (49)
Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation. (1998) (49)
Nasal provocation with allergen induces a secondary serum IgE antibody response. (1997) (49)
Histamine release due to bivalent penicilloyl haptens the relation of activation and desensitization of basophils to dynamic aspects of ligand binding to cell surface antibody. (1979) (49)
STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA (1964) (49)
Studies on the relationships between sensitivity to cold, dry air, hyperosmolal solutions, and histamine in the adult nose. (1990) (49)
The modulation of human basophil histamine release by products of the 5-lipoxygenase pathway. (1982) (48)
Induction of IgE-mediated immediate hypersensitivity to group I rye grass pollen allergen and allergoids in non-allergic man. (1972) (48)
Prevalence of hymenoptera venom allergy (1982) (48)
Regulation of IgE-dependent IL-4 generation by human basophils treated with glucocorticoids. (1997) (47)
Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine. (1992) (47)
GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. (1993) (47)
Immunoglobulin E-mediated release of a kininogenase from purified human lung mast cells. (1985) (46)
Differences in the volume distributions of human lung mast cell granules and lipid bodies: evidence that the size of these organelles is regulated by distinct mechanisms (1985) (45)
Anaphylactic release of prostaglandins from human lung in vitro. (1980) (44)
Maintenance immunotherapy in ragweed hay fever. Booster injections at six week intervals. (1971) (44)
Eosinophil chemotactic factor (ECF). II. Release from human polymorphonuclear leukocytes during phagocytosis. (1976) (44)
Possible role of phospholipase A2 in triggering histamine secretion from human basophils in vitro. (1981) (44)
Evaluation of the quantity and affinity of human IgG "blocking" antibodies. (1979) (43)
The pharmacologic modulation of the release of arachidonic acid metabolites from purified human lung mast cells. (1985) (43)
Basophils and eosinophils in allergic rhinitis. (1994) (43)
RELATIONSHIP TO SERUM IgE CONCENTRATION (1978) (43)
Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. (1991) (43)
The mechanism of mediator release from human basophils induced by platelet-activating factor. (1990) (43)
Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. (1995) (43)
F-met peptide-induced degranulation of human basophils. (1991) (43)
Assessment of prolonged venom immunotherapy in children. (1987) (42)
Qualitative characteristics of histamine release from human basophils by covalently cross-linked IgE. (1981) (42)
Antigen-provoked increase in histamine reactivity. Observations on mechanisms. (1991) (41)
Production of granulocyte/macrophage colony-stimulating factor in human airways during allergen-induced late-phase reactions in atopic subjects. (1992) (41)
Appearance of granulocyte-macrophage colony-stimulating factor activity at allergen-challenged cutaneous late-phase reaction sites. (1993) (41)
Effect of prostaglandin D2 in modulating histamine release from human basophils. (1984) (41)
Rapidly released allergens from short ragweed pollen. I. Kinetics of release of known allergens in relation to biologic activity. (1981) (41)
The use of in vitro tests for IgE antibody in the specific diagnosis of IgE-mediated disorders and in the formulation of allergen immunotherapy. American Academy of Allergy and Immunology. (1992) (41)
The pattern and kinetics in human skin of erythema and mediators during the acute and late-phase response (LPR). (1989) (40)
Experimentally induced nasal allergic responses. (1988) (40)
215 Immunostimulatory oligonucleotides conjugated to Amb a 1: Safety, skin test reactivity, and basophil histamine release (2000) (40)
The development of negative skin tests in children treated with venom immunotherapy. (1984) (40)
Antibody response following immunotherapy in ragweed hay fever: Allpyral vs. whole ragweed extract. (1968) (39)
Treatment failures with whole-body extract therapy of insect sting allergy. (1981) (39)
Indomethacin enhances response of human bronchus to antigen. (1985) (39)
Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid (1991) (39)
Comparison between skin-sensitizing antibody titers and leukocyte sensitivity measurements as an index of the severity of ragweed hay fever. (1967) (38)
Differences between histamine release from rat mast cells and human basophils and mast cells (1979) (37)
Release of slow reacting substance of anaphylaxis from human leukocytes. (1974) (37)
Effects of antihistamines on the cardiopulmonary changes due to canine anaphylaxis. (1988) (37)
Studies on ragweed pollen allergens. V. (1967) (37)
IL‐4 secretion and histamine release by human basophils are differentially regulated by protein kinase C activation (1998) (37)
Diagnosis of Hymenoptera hypersensitivity by skin testing with Hymenoptera venoms. (1977) (37)
The effect of terfenadine on unilateral nasal challenge with allergen. (1994) (37)
Beta-adrenergic blockers, immunotherapy, and skin testing (1989) (37)
Protection against anaphylaxis in hymenoptera-sensitive patients by passive immunization. (1977) (37)
Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones. (1997) (36)
In vivo model for the evaluation of topical antiallergic medications. (1984) (35)
Antigen‐specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen‐induced late phase reactions (2001) (35)
Is histamine responsible for the symptoms of rhinovirus colds? A look at the inflammatory mediators following infection. (1988) (35)
In vivo suppression of the immune response to alloantigen by cholera enterotoxin. (1973) (35)
Activated human basophils contain histamine in cytoplasmic vesicles. (1994) (35)
The waiting period after allergen skin testing and immunotherapy. American Academy of Allergy and Immunology. (1990) (34)
Lipid Bodies: Widely Distributed Cytoplasmic Structures That Represent Preferential Nonmembrane Repositories of Exogenous [3H]Arachidonic Acid Incorporated by Mast Cells, Macrophages, and Other Cell Types (1985) (34)
Reversed in vitro anaphylaxis induced by anti-IgG: specificity of the reaction and comparison with antigen-induced histamine release. (1972) (34)
Nasal secretory antibody to inhalant allergens in allergic and non-allergic patients. (1970) (34)
Qualitative differences between dimeric and trimeric stimulation of human basophils. (1983) (34)
Recombinant stem cell factor-induced mast cell activation and smooth muscle contraction in human bronchi. (1994) (34)
The relationship of in vitro and in vivo allergic histamine release: inhibition in primates by cAMP active agents. (1972) (34)
Basic characteristics of human lung mast cell desensitization. (1987) (34)
Clinical and immunologic effects of component peptides in Allervax Cat. (1997) (33)
Differences between basophils and mast cells: failure to detect Charcot-Leyden crystal protein (lysophospholipase) and eosinophil granule major basic protein in human mast cells. (1986) (33)
Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. (1984) (33)
The role of basophils in inflammatory reactions. (1978) (33)
Studies on the mechanism of hypersensitivity phenomena. XI. The effect of normal human serum on the release of histamine from human leukocytes by ragweed pollen antigen. (1966) (33)
A comparison of venom treatment and no treatment in insect allergic children (1982) (33)
Mediator release from human basophils and mast cells from lung and intestinal mucosa. (1985) (33)
Inhibition of human basophil leukotriene release by antiinflammatory steroids. (1985) (33)
In vitro basophil histamine release induced by mannitol in a patient with a mannitol-induced anaphylactoid reaction. (1984) (32)
The concept of basophil releasability. (1986) (32)
Anti-human IgG causes basophil histamine release by acting on IgG-IgE complexes bound to IgE receptors. (1992) (32)
Prostaglandin D2 and histamine during the immediate and the late-phase components of allergic cutaneous responses. (1988) (32)
In vitro assay of allergenic properties of ragweed pollen antigens. (1966) (32)
Preferential recruitment of activated, memory T lymphocytes into skin chamber fluids during human cutaneous late-phase allergic reactions. (1995) (32)
Relationship between histamine and physiological changes during the early response to nasal antigen provocation. (1999) (32)
Role of receptor aggregation in triggering IgE-mediated reactions. (1982) (32)
Effects of loratadine and terfenadine on the induced nasal allergic reaction. (1996) (31)
Diamine oxidase-gold labels histamine in human mast-cell granules: a new enzyme-affinity ultrastructural method. (1993) (31)
An evaluation of the role of immunotherapy in asthma. (1978) (31)
Cyclic AMP agonist inhibition increases at low levels of histamine release from human basophils. (1981) (31)
Sequential analysis of the allergic response: cyclic AMP, calcium and histamine. (1975) (30)
An antigen-activated DFP-inhibitable enzyme controls basophil desensitization. (1984) (30)
Vesicular transport of histamine in stimulated human basophils. (1996) (30)
Failure of the putative IgE pentapeptide to compete with IgE for receptors on basophils and masts cells. (1977) (30)
The effect of a leukotriene antagonist on the early response to antigen (1990) (30)
Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids. (1986) (29)
Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI. (1999) (29)
Preparation and immunochemical properties of methoxypolyethylene glycol-coupled and N-carboxymethylated derivatives of ragweed pollen allergen, antigen E. (1977) (29)
Differential regulation of human, antigen-specific Th1 and Th2 responses by the B-7 homologues, CD80 and CD86. (1997) (29)
Cold dry air-induced rhinitis: effect of inhalation and exhalation through the nose. (1995) (29)
CHAPTER 7 – The Control of IgE-Mediated Histamine Release: Implications for the Study of Asthma* (1973) (29)
Anaphylactic release of a prekallikrein activator from human lung in vitro. (1983) (29)
Spontaneous histamine release after exposure to hyperosmolar solutions. (1986) (29)
Cytokine generation by human basophils. (1994) (28)
Bilateral increases in histamine after unilateral nasal allergen challenge. (1997) (27)
IgE mediated histamine release: in vitro separation into two phases. (1971) (27)
Heavy Water Enhances IgE-Mediated Histamine Release from Human Leukocytes: Evidence for Microtubule Involvement 1 (1972) (27)
Allergy to insect sting. III. Allergenic cross-reactivity among the vespid venoms. (1976) (27)
Anaphylactic relase of a basophil kallikrein-like activity. II. A mediator of immediate hypersensitivity reactions. (1979) (27)
Theophylline reduces the response to nasal challenge with antigen. (1985) (27)
IgE‐Mediated Basophil Phenomena: Quantitation, Control, Inflammatory Interactions (1978) (27)
Increased expression of osteopontin is associated with long-term bee venom immunotherapy. (2005) (26)
Platelet activation in antigen-induced bronchoconstriction. (1981) (26)
An ultrastructural analysis of tumor-promoting phorbol diester-induced degranulation of human basophils. (1992) (26)
Abnormalities of basophil "releasability" in atopic and asthmatic individuals. (1986) (26)
Purified human basophils and mast cells: current concepts of mediator release. (1983) (26)
Cells and secretagogues involved in the human late-phase response. (1989) (25)
Protein kinase C modulates immunoglobulin E-mediated activation of human mast cells from lung and skin. I. Pharmacologic inhibition. (1991) (25)
Differential regulation of antigen-induced IL-4 and IL-13 generation from T lymphocytes by IFN-alpha. (1999) (25)
Intestinal mast cell responses in idiopathic inflammatory bowel disease (1993) (25)
H2 antihistamines augment antigen-induced histamine release from human basophils in vitro. (1982) (25)
Generation of slow reacting substance by human leukocytes. II. Comparison of stimulation by antigen, anti-IgE, calcium ionophore, and C5-peptide. (1980) (25)
Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. (1988) (25)
A reevaluation of immunotherapy for asthma. (1984) (24)
Function and expression of adhesion molecules on human basophils. (1994) (24)
Comparisons of alum-precipitated and unprecipitated aqueous ragweed pollen extracts in the treatment of hay fever. (1978) (24)
Mechanisms of contraction induced by partially purified slow reacting substance from human polymorphonuclear leukocytes and leukotriene D in guinea pig ileal smooth muscle. (1981) (24)
Human mast cells and basophils-structure, function, pharmacology, and biochemistry (1983) (24)
Mediator release after allergic and physical nasal challenges. (1985) (24)
Is desensitization' for ragweed hay fever immunologically specific? (1972) (24)
Histamine distribution in human basophil secretory granules undergoing FMLP-stimulated secretion and recovery. (1995) (24)
The allergens responsible for house dust allergy: I. Comparison of Dermatophagoides pteronyssinus and house dust extracts by assay of histamine release from allergic human leukocytes☆ (1972) (24)
Effect of theophylline and terbutaline on immediate skin tests. (1980) (24)
In vivo and in vitro effects of antihistamines on mast cell mediator release: a potentially important property in the treatment of allergic disease. (1989) (24)
Sensitization following Hymenoptera whole body extract therapy. (1978) (24)
130 Immunologic response to sequential stings after stopping venom immunotherapy (VIT) in adults (1988) (23)
Local application of atropine attenuates the upper airway reaction to cold, dry air. (1992) (23)
Human allergic reactions. (1969) (23)
Dexamethasone inhibits the antigen-induced contractile activity and release of inflammatory mediators in isolated guinea pig lung tissue. (1987) (23)
Cyclic nucleotides in immune responses and allergy. (1980) (23)
Immunochemical studies of dextran coupled ragweed pollen allergen, antigen E. (1975) (23)
Passive sensitization of human basophils: evidence for heterogeneity in the IgE molecule. (1979) (23)
IgE-induced changes in human basophil cyclic AMP levels. (1978) (23)
Nasal challenge with cold, dry air induces a late-phase reaction. (1988) (23)
Histamine release in acute anaphylactic enteropathy of the rat. (1984) (22)
Purified human basophils do not generate LTB4. (1987) (22)
Steroid-induced reduction of histamine release does not alter the clinical nasal response to cold, dry air. (1991) (22)
Some invariant properties of IgE-mediated basophil activation and desensitization. (1979) (22)
The effects of antihistamines beyond H1 antagonism in allergic inflammation. (1990) (22)
Pharmacologic and biochemical studies of human lung mast cells (MC) (1982) (21)
Human Lung Mast Cell and Alveolar Macrophage Cytoplasmic Lipid Bodies Contain Arachidonic Acid and Prostaglandin Endoperoxide Synthase (Cyclooxygenase), the Substrate and Enzyme Necessary for Prostaglandin Production. (1992) (21)
Studies of the intracellular Ca2+ levels in human adult skin mast cells activated by the ligand for the human c-kit receptor and anti-IgE. (1994) (21)
Limited proteolysis of antigens E and K from ragweed pollen. (1981) (20)
Mechanisms of mediator release from human skin mast cells upon stimulation by the bradykinin analog, [DArg0-Hyp3-DPhe7]bradykinin. (1991) (20)
Inhibition by adenosine of histamine and leukotriene release from human basophils. (1989) (20)
216 Conjugation of immunostimulatory DNA (ISS) to the major short ragweed allergen, Amb a 1, enhances immunogenicity and reduces allergenicity (2000) (20)
Immunologic responses to conjugates of antigen E in patients with ragweed hay fever. (1984) (19)
Defective release of eosinophil chemotactic factor from peripheral leukocytes in patients with chronic urticaria. (1976) (19)
Control mechanisms of histamine release from human basophils in vitro: the role of phospholipase A2 and of lipoxygenase metabolites. (1981) (19)
Histamine-containing cells in human peritoneal fluid. (1984) (18)
Level of osteopontin is increased after bee venom immunotherapy. (2005) (18)
In vitro studies of rye grass pollen antigens. (1969) (18)
Large local reactions following hymenoptera stings in children (1982) (18)
Case report of venom immunotherapy for a patient with large local reactions. (2001) (18)
Histamine release from human leukocytes: relationships between cyclic nucleotide, calcium, and antigen concentrations. (1975) (18)
The interaction of cytokines with human basophils and mast cells. (1995) (17)
Lipid mediators of the allergic reaction. (1990) (17)
Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin. (1990) (17)
Origin of late phase histamine release. (1996) (17)
The pathophysiology of human mast cells. In vitro and in vivo function. (1987) (17)
Comparative ultrastructural morphology of human basophils stimulated to release histamine by anti-IgE, recombinant IgE-dependent histamine-releasing factor, or monocyte chemotactic protein-1. (1996) (16)
Ketotifen reduces sneezing but not histamine release following nasal challenge with antigen (1990) (16)
Vesicular transport of Charcot-Leyden crystal protein in tumor-promoting phorbol diester-stimulated human basophils. (1996) (16)
Prostaglandin Inhibition of Immediate and Delayed Hypersensitivity in Vitro (1972) (16)
The pharmacologic control of mediator release from human basophils and mast cells. (1986) (16)
Studies on the immunological relationship of ragweed pollen antigens E and Ra.3. (1973) (15)
Treatment of ragweed hay fever with urea-denatured antigen E. (1980) (15)
Effect of oxymetazoline on the early response to nasal challenge with antigen. (1993) (15)
206 Human immune response to hymenoptera venoms (1983) (15)
Kinetic analysis of histamine release due to covalently linked IgE dimers. (1982) (15)
A comparative study of the effects of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet activating factor on histamine and leukotriene C4 release from human leukocytes. (1993) (15)
Diamine oxidase‐gold ultrastructural localization of histamine in isolated human lung mast cells stimulated to undergo anaphylactic degranulation and recovery in vitro (1996) (15)
Vesicular transport of Charcot-Leyden crystal protein in f-Met peptide-stimulated human basophils. (1997) (15)
Effects of a specific inhibitor of the 5-lipoxygenase pathway on mediator release from human basophils and mast cells. (1988) (14)
Indomethacin, arachidonic acid metabolism and basophil histamine release. (1979) (14)
Histamine, 5-Hydroxytryptamine, SRS-A: Discussion of Type I Hypersensitivity (Anaphylaxis) (1978) (14)
The effect of a histamine synthesis inhibitor on the immediate nasal allergic reaction (1987) (14)
In vitro resistance to dexamethasone of basophils from patients receiving long-term steroid therapy. (1985) (13)
The pharmacologic modulation of mediator release from human basophils. (1988) (13)
Clinical pharmacology of acute allergic disorders. (1980) (13)
The Interdependence of Allergic and Inflammatory Processes (1976) (13)
Capacity of purified antigens and whole pollen extracts to release histamine from leukocytes of hay fever patients. (1973) (13)
Current therapy in allergy and immunology 1983-1984 (1983) (13)
The action of strontium on basophil leukocytes and its use to probe the relationship between immunologic stimulus and secretory response. (1979) (13)
Pharmacologic control of histamine release from human basophils induced by platelet-activating factor. (1993) (13)
Activation of basophils. (1986) (13)
Inhibitability and enhanceability of basophil histamine release in asthmatic and normal subjects. (1985) (12)
Role of Basophils in Human Allergic Disease. (1992) (12)
Bradykinin analog induce histamine release from human skin mast cells. (1989) (12)
IgE-dependent histamine-releasing factors. A brief review. (1991) (12)
141. Development of long-lasting immediate hypersensitivity in nonatopic volunteers parenterally immunized with a purified grass pollen extract (1978) (12)
Mediators and the mechanism of their release. (1978) (12)
Histamine release from human basophils induced by platelet activating factor: the role of extracellular calcium, interleukin-3, and granulocyte-macrophage colony-stimulating factor. (1995) (12)
Activation of Hageman factor by proteases released during antigen challenge of human lung. (1981) (12)
Measurement of circulating IgG and IgE food-immune complexes. (1988) (12)
392 Risk and benefit of discontinuing venom immunotherapy (VIT) after 5 years (1991) (12)
Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. (1984) (12)
Postscript to bee stings: delayed 'serum sickness'. (1983) (12)
Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK). (1998) (11)
Mechanisms and Pharmacologic Control of Basophil–Derived IL–4 and IL–13 (1999) (11)
The nasal late-phase response--an in vivo model. (1988) (11)
Lipid Mediators of the Allergic Reaction (Part 1 of 2) (1990) (11)
The effects of H1 antihistamines on the early allergic response. (1989) (11)
Failure to obtain histamine release from rat mast cells exposed to human allergic serum and specific antigen or IgE myeloma protein and anti-IgE. (1973) (11)
Ultrastructural Autoradiographic Analysis of RNA in Isolated Human Lung Mast Cells during Secretion and Recovery from Secretion (2000) (11)
Observations on nasal late phase reactions. (1987) (11)
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? (1994) (11)
285 In vivo release of histamine by hyperosmolar stimuli (1985) (10)
Lipoxygenase products of arachidonic acid: role in modulation of IgE-induced histamine release. (1982) (10)
Treatment with hot, humid air reduces the nasal response to allergen challenge. (1997) (10)
37 Cold, dry air (CDA) and histamine (HIST) induce more potent responses in perennial rhinitics compared to normal individuals (1991) (10)
The effect of an H2 receptor antagonist on immediate and delayed skin test reactivity in man (1979) (10)
Eosinophil Chemotactic Factor (ECF) (1976) (10)
Is leukotriene B4 an important mediator in human IgE-mediated allergic reactions? (1987) (10)
The role of prostaglandin D2 in IgE-mediated reactions in man. (1982) (10)
Comparative Studies of Histamine Release and Potassium Efflux From Human Leukocytes.∗ (1966) (10)
Prevention of canine anaphylaxis with isoproterenol. (1986) (10)
Asthma, physiology, immunopharmacology, and treatment : second international symposium (1977) (10)
Dual Transmembrane Signalling Mechanisms in Eosinophils: Evidence for Two Functionally Distinct Receptors for Platelet-Activating Factor. (1992) (10)
208 Do all children with insect allergy need venom therapy (1983) (10)
414 Is venom immunotherapy (VIT) forever (1985) (10)
655 Antigen-induced eosinophil activation and recruitment in the lower airways (1991) (10)
Recovery of human basophils after FMLP‐stimulated secretion (1996) (10)
Immunopharmacology of Nasal Allergic Reactions (1988) (10)
Activation of the Hageman Factor-Dependent Systems during IgE-Mediated Reactions of the Human Lung (1981) (9)
Effects of a single-dose pretreatment with captopril on the immediate response to nasal challenge with allergen. (1990) (9)
Long-term immunotherapy with ragweed allergen and allergoid (1979) (9)
456 Nasal challenge with antigen (AG) leads to increased sensitivity to histamine (1988) (9)
142. The effects of oral theophylline and terbutaline on skin tests and histamine release (1978) (9)
Inhibition of human polymorphonuclear leukocyte-derived histaminase activity by H-2 antagonists. (1978) (9)
19 Interaction between hyperosmolar and IgE induced histamine release from basophils and mast cells (1983) (9)
Heterogeneity of human mast cells and basophils. Effects of a putative 5-lipoxygenase inhibitor. (1989) (9)
Histamine release due to bivalent penicilloyl haptens: control by the basophil plasma membrane. (1978) (9)
Localized antigen challenge of the nasal mucosa. (1990) (9)
The Role of Leukotrienes in Human Pathophysiology a (1988) (9)
Analysis of mast cell activation using diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. (1995) (8)
The role of adenosine in the control of immune function (1980) (8)
Antigen-induced eosinophil chemotactic factor (ECF) release by human leukocytes (1976) (8)
The role of inhalation challenge. (1975) (8)
The Role of the Cyclic AMP System in Inflammation: An Introduction (1974) (8)
The role of kinins in human allergic disease. (1986) (8)
Mediator release from human lung under conditions of reduced oxygen tension. (1986) (8)
Paclitaxel hypersensitivity revisited. (1996) (8)
Adenosine receptors on human basophils and lung mast cells. (1986) (8)
Studies with purified human basophils and mast cells. (1983) (8)
Eosinophils chemotactic factor (ECF). IV. Inhibitory activity in human peripheral leukocytes. (1978) (8)
Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions. (2003) (8)
224 In vivo response to platelet derived histamine releasing factor (1988) (7)
Enhanced IL-10 secretion by PBMC during the ragweed season: Effect of AIC immunotherapy vs placebo (2003) (7)
24. The immune response to hymenoptera venoms (1978) (7)
Spontaneous histamine secretion from leukocytes in the presence of strontium. (1979) (7)
Immunologic and clinical responses to ragweed extract and its allergoid (1975) (7)
Justifying a mechanism-based specialty. (1996) (7)
IgE and IgG antibody response to purified bee‐venom antigens and peptides in four patients who had adverse reactions to immunotherapy (1988) (7)
The β-adrenergic blockade theory of asthma: Fact or fantasy? (1973) (7)
8. Adenosine-adenosine deaminase modulation of histamine release (1978) (7)
Pharmacology of upper airways challenge. (1987) (7)
533 Human recombinant interleukin 3 (IL3) induces histamine release from human basophils (1988) (7)
128 Starting and stopping venom immunotherapy (VIT) in children with insect allergy (1988) (7)
Chlorphenesin: a new inhibitor of IgE-mediated histamine release. (1969) (6)
The allergens responsible for house dust allergy. (1972) (6)
98. Basophil “releasability” in patients with intrinsic asthma (1978) (6)
Mast cells and basophils: effector cells of inflammatory disorders in the lung. (1981) (6)
176 Effects of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late phase response(LPR) (1988) (6)
Penicillin hypersensitivity in systemic lupus erythematosus. (1975) (6)
IgE and IgG antibody responses during immunotherapy (1973) (6)
The role of complement in human immediate hypersensitivity: evidence against involvement of the alternate pathway of complement activation. (1973) (6)
Rinkel method of immunotherapy for ragweed hay fever (1979) (6)
503 Two-year study of clinical results after discontinuation of ragweed allergoid immunotherapy (1988) (6)
Anaphylactic Reactions to Insect Stings: A New Approach (1975) (6)
Mediator Release: Studies with Purified Human Basophils and Mast Cells (1983) (6)
4 Mediator release following antigenic nasal challenge (1983) (6)
83 Osmotically activated human lung mast cells (MC) and basophils release histamine but not arachidonic acid metabolites (1985) (6)
In Vitro and In Vivo Model Systems for the Study of Allergic and Inflammatory Disorders in Man : Implications for the Pathogenesis of Asthma (1985) (6)
Immunologic and Physiologic Changes During Canine Anaphylaxis and Asthma (1985) (6)
Once stung, twice shy. When should insect sting allergy be treated? (1980) (6)
IgE-mediated release of inflammatory mediators from human basophils and mast cells in vitro and in vivo (1984) (6)
Basophil mediators and their release, with emphasis on BK-A. (1980) (6)
Anaphylaxis and stinging insect hypersensitivity. (1987) (6)
531 The effect of cytokines on human basophils (1988) (6)
Dimeric IgE may not represent the unit signal for the release of all mediators in human basophils (1984) (5)
Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin (1986) (5)
Diabetes insipidus with hypersensitivity to pitressin. An immunological study. (1972) (5)
Augmentation of antigen-stimulated histamine release from human basophils by serum-treated zymosan particles. II. Dependence on IgE-mediated release. (1979) (5)
Immunotherapy of Allergic Disorders: Traditional and Novel Approaches. (1992) (5)
Blocking antibody to bee venom: induction by venom and not by whole body extracts (1974) (5)
The Immunologic Basis for the Efficacy of Immunotherapy (1983) (5)
207 Immunologic effects of prolonged venom immunotherapy in children (1983) (5)
654 GM-CSF enhances PAF- and FMLP-induced eosinophil expression of adherence molecules (CD11b) and increases FMLP-induced adherence to endothelial cells (1991) (5)
The role of cyclic amp in the specific cytolytic activity of lymphocytes. Abstr. (1972) (5)
Augmentation of antigen-stimulated histamine release from human basophils by serum-treated zymosan particles. I. Characteristics of enhancement. (1979) (5)
5 Characterization of ragweed sensitive patients by nasal challenge with pollen (1983) (5)
Origin of PGF2 alpha production following anaphylactic challenge of human lung. (1979) (5)
The great debate: Immunotherapy and asthma (1986) (5)
Modulation of the rate of histamine release from basophils by cyclic AMP. (1980) (5)
36 Epithelial cell detachment is observed during the nasal reaction to cold, dry air (CDA) (1991) (5)
19. Maintenance immunotherapy for hymenoptera sensitivity (1978) (5)
Adenosine-adenosine deaminase modulation of histamine release from human basophilsin vitro (1979) (5)
703 Human recombinant IgE-dependent histamine releasing factor (HrHRF) enhances IL-4 secretion by human basophils (1996) (5)
Nearly fatal anaphylaxis following an insect sting. (1994) (5)
Antigen- and histamine H1 receptor-mediated relaxation of guinea pig isolated trachea. (1987) (5)
Specific IgE antibody measurements in the diagnosis of ragweed hay fever (1973) (4)
The role of inflammatory mediators in allergic rhinitis. (1986) (4)
Hymenoptera sensitivity. Diagnostic and therapeutic studies. (1975) (4)
Mediators in nasal secretions of patients with allergic rhinitis (1985) (4)
Asthma induced by exposure to living cats (1982) (4)
79. Augmentation of IgE-mediated histamine release from human basophils by phagocytic stimuli (1978) (4)
271 Allergen-induced late-phase reaction (LPR) sites contain IL-3 and GM-CSF activity (1991) (4)
133 Dexamethasone (DEX) selectively inhibits IL-3 priming of basophil, C5a responses (1991) (4)
Treatment of honeybee anaphylactic sensitivity with honeybee venom: A case report (1974) (4)
Hymenoptera anaphylaxis: Diagnostic use of pure venoms (1973) (4)
65. Mechanism of anaphylactic release of prostaglandins (PGs) from human lung (1978) (4)
Effects of anti-histamine agents on immunologic and physiologic alterations during canine anaphylaxis (1982) (4)
20. Immunotherapy with commercial venom preparations (1978) (4)
Pharmacologic control of IgE-mediated histamine release from human leukocytes. (1973) (4)
Beta-adrenergic blockers, immunotherapy, and skin testing. American Academy of Allergy and Immunology. (1989) (4)
Mediator Release from Basophils and Mast Cells and Its Relationship to FcRI Expression and IgE-Suppressing Therapies (2002) (3)
Kininogens in nasal secretions after allergen challenge. (1986) (3)
Responses to conjugated AgE in ragweed hay fever (1982) (3)
Mast cells and mast cell mediators in models of airway disease. (1985) (3)
Modulation of cyclic AMP in human leukocytes by physiological doses of adenosine (1978) (3)
49 Persistent efficacy of a combination antihistamine/analgesic/decongestant product (CAAD) the morning after a bedtime dose (1991) (3)
1102 Sting challenge (SC) trial III. Variable affecting the outcome of insect sting (2000) (3)
Kinins as mediators of human allergic reactions. (1986) (3)
IgE-mediated leukotriene release in vitro and in vivo. (1984) (3)
186 Insect allergy: Sting outcome in history-positive, skin-test negative children (1985) (3)
1101 Sting challenge (SC) trial IV. The history-positive skin test-negative patients (2000) (3)
Mechanisms of basophil recruitment in allergic diseases. (1992) (3)
Effect of Recombinant Human c-kit Receptor Ligand on Mediator Release from Human Skin Mast Cells. (1992) (3)
II. A MEDIATOR OF IMMEDIATE HYPERSENSITIVITY REACTIONS (1979) (3)
Venom immunotherapy for hymenoptera sensitivity: results in whole body extract (WBE) treatment failures and newly diagnosed patients (1976) (3)
403 Differential modulation of mediator release in human basophils (1991) (3)
429 Immunomodulatory efficacy of selective phosphodiesterase (PDE) inhibitors on antigen-specific T cell clones (TCC) (1996) (3)
Heterogeneity of human Fc epsilon RI-bearing cells. (1989) (2)
Interferon-beta induces selective enhancement of antigen-specific T cell responses. (2000) (2)
233 ISS conjugated to Amb a 1 allergen promotes a Th2 to Th1 switch in PBMC from Ragweed-allergic humans (2000) (2)
Effect of solvent on the histamine-releasing, enzyme-releasing, and mitogenic properties of the calcium ionophore A23187. (1979) (2)
Evaluation and Treatment of Insect Sting Allergy (1981) (2)
227 Correlation of basophil responsiveness to platelet-derived Histamine Releasing Factor (PD-HRF) and deuterium oxide (D2O) (1988) (2)
Platelet augmentation of basophil histamine release (1982) (2)
460 The relationship between atopy and the response to cold dry air (CDA) and histamine (H) challenge in perennial rhinitis (PR) (1988) (2)
Role of complement in human immediate hypersensitivity: Evidence against requirement of C3 for IgE-mediated histamine release (1973) (2)
THE ROLE OF LIPOXYGENASE PRODUCTS OF ARACHIDONIC ACID IN INFLAMMATORY EVENTS MEDIATED BY HUMAN BASOPHILS AND MAST CELLS (1983) (2)
337 Human recombinant IgE-dependent histamine releasing factor (HrHRF) primes basophils for histamine release (1996) (2)
Presidential address. Fiftieth annual meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994. (1995) (2)
Studies with 14C-labeled ragweed antigens: Decreased antigen uptake by leukocytes of ragweed-sensitive individuals (1973) (2)
Arachidonic acid (AA) metabolism and antigen-induced bronchospasm (1981) (2)
Laboratory Diagnosis of Immediate Hypersensitivity Disorders (1979) (2)
Mediators during cutaneous allergic immediate and late phase reactions (1984) (2)
Allergic responses to airborne allergens and insect venoms. (1977) (2)
Dispersed Human Lung Mast Cells (2015) (2)
Augementation of Antigen-Stimulated Histamine Release from Human Basophils by Serum-Treated Zymosan Particles (1979) (1)
Lipoxygenase Products of Arachidonic Acid: their Role in Inflammatory Events Mediated by Human Basophils and Mast Cells (1983) (1)
424 In vitro synthesis of antigen specific IgE (1991) (1)
Differences between antigen and anti immuno globulin e induced basophil histamine release (1979) (1)
Allergy to insect stings. (1978) (1)
Granulocyte Functions in Immunological Reactions (1971) (1)
443 Improved intrapulmonary delivery of aerosol using a new medication delivery system (1988) (1)
In vitro approach to problems in clinical allergy. (1968) (1)
Evaluation of a bedtime dose of a combination antihistamine/analgesic/decongestant product on antigen challenge the next morning (1992) (1)
408 The effects of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine (AAPC) on human basophil mediator release (1991) (1)
Allergenicity of Hybrid Ag 5s of Yellow Jacket and Paper Wasp Venoms (2001) (1)
Stability of hymenoptera venom skin test extracts (2003) (1)
137. An analysis of immunotherapy: allergoid versus allergen (1978) (1)
692 VENOM IMMUNOTHERAPY FOR INSECT HYPERSENSITIVITY (1978) (1)
Treatment of immediate hypersensitivity reactions to drugs. (1974) (1)
Generation of kinins in vivo during allergic rhinitis (1988) (1)
Venom immunotherapy (VIT) for large local reactions (LLR) to insect stings: A pilot study☆ (2004) (1)
Immunotherapy in hypersensitivity to insects. (1978) (1)
158. Positive correlation of total IgE receptors on human basophils and serum IgE level (1978) (1)
The pathophysiology of allergic rhinitis and its implications for management (1993) (1)
17 D2O-induced basophil histamine release in asthmatic subjects: Secondary to C′ activation products? (1983) (1)
Contents, Vol. 94, 1991 (1991) (1)
Anaphylactic Release of Prostaglandins from Human Lung (1980) (1)
Osteopontin: A potential biomarker for successful allergen immunotherapy (2004) (1)
/sup 3/H arachidonic acid incorporation and metabolism in purified human basophils (1986) (1)
138 Corticosteroids inhibit the cutaneous late-phase response (LPR) to allergen by blocking the influx of eosinophils and basophils (1991) (1)
Therapy of vespid allergic patients with vespid venoms: Immunologic consequences (1975) (1)
Reactions on ragweed immunotherapy (1982) (1)
Activation of human Hageman factor by a leukocytic protease. (1979) (1)
Generation and release of eosinophil chemotactic factor from human polymorphonuclear leukocytes. (1977) (1)
Heterogeneity of Human FcϵRI‐Bearing Cells (2007) (1)
200 The effect of a histamine synthesis inhibitor on the immediate allergic reaction (1985) (1)
458 Localized antigen challenge of the nasal mucosa (1988) (1)
815 Intravenous administration of a potential T cell toleragenic peptide to cat sensitive patients (1996) (1)
508 Specific IgE antibodies in serum and in bronchoalveolar (BAL) fluid correlate with the magnitude of the antigen-induced late phase reaction (1996) (0)
ADENOSINE RECEPTORS ON HUMAN BASOPHILS AND LUNG MAST CELLS: 122 (1985) (0)
The specificity of the histamine receptor on cytolytically active t cells. Abstr. (1973) (0)
Contents, Vol. 82, 1987 (1987) (0)
I. PURIFICATION AND CHARACTERIZATION (1979) (0)
492 Effects of immunotherapy on early and late reactions to nasal challenge (1988) (0)
[Treatment of immediate drug hypersensitivity]. (1975) (0)
Current therapy in allergy, immunology, and rheumatology, 1985-1986 (1985) (0)
Subject Index, Vol. 113, 1997 (1997) (0)
Eosinophil chemotactic factor (ECF). III. Generation in human peripheral leukocytes. (1978) (0)
Conversations about Asthma (1998) (0)
452 Lack of specificity of B7 homologues in human Th1 and Th2 responses (1996) (0)
Natural history of allergy to insect venom and stings (2000) (0)
Immunosuppression in vivo by cholera enterotoxin of the immune response to transplantation antigens. (1973) (0)
Contents, Vol. 66, Supplement 1, 1981 (1981) (0)
[The role of primary chemical mediators in anaphylactic and inflammatory reactions]. (1982) (0)
Chlorphenesin: a new inhibitor IgE-mediated histamine release. (1969) (0)
Diagnosis and treatment of venom allergy: Overview (1979) (0)
Contents, Vol. 99, 1992 (1992) (0)
Contents, Vol. 99, 1992 (1992) (0)
Contents, Vol. 99, 1992 (1992) (0)
Sting Challenge TrialV. Patient population and location May affect outcome (2002) (0)
Contents, Vol. 102, 1993 (1993) (0)
Biographical Sketch of Dr. Alec H. Sehon (1991) (0)
Round Table Conference on Allergen Standardization (1971) (0)
Immunopharmacology of inflammation: Modulation of the release of chemical mediators from human inflammatory cells by auranofin (1985) (0)
HYPEROSMOLAR MEDIATOR RELEASE FROM HUMAN BASOPHILS AND MAST CELLS (1984) (0)
Average affinity of IgE antibody determines the concentration of antigen required for optimal histamine release from human basophils (1985) (0)
Differences in the Behavior Lipid Bodies during Human of Cytoplasmic Granules and Lung Mast Cell Degranulation (2003) (0)
Atopic allergy and other hypersensitivities. (1990) (0)
Contents, Vol. 43, 1972 (1972) (0)
Contents, vol. 50, Supplement 2, 1986 (1986) (0)
The Metabolism of Arachidonic Acid by Purified Human Lung Mast Ceils (1985) (0)
Selective inhibition of cyclooxygenase product release from human lung fragments by dexamethasone (1984) (0)
Immunologic aspects of human reaginic allergy: An in vitro method and some applications (1965) (0)
The suppression of the immune response in vivo by cholera enterotoxin. Abstr. (1973) (0)
Session 3. Immune cells in allergic disorders (2004) (0)
Physiologic Manifestations of Human Anapf is (1980) (0)
The Pathophysiology of Human Mast Cells (2015) (0)
778 Human IgG supports mediator release from basophils (1991) (0)
Release of histamine from human leukocytes: Unique interaction of phorbol diester with other stimuli (1981) (0)
Mini Symposium 1: Insect venom hypersensitivity (2002) (0)
30 Kininogens in nasal secretions of allergic individuals (1985) (0)
Profiling of allergen-induced gene expression in subjects with bee venom allergy* (2003) (0)
Contents, Vol. 76, 1985 (1985) (0)
Alkaline earth ions and the secretion of enzymes from human neutrophil leucocytes [proceedings]. (1979) (0)
Dim Regard for Clinical Allergy (1972) (0)
Hay Fever Symptoms, Blocking Antibody Levels, and Leucocyte Histamine Release in Patients Receiving Very High Dosage Immunotherapy with Ragweed Pollen Extract (2009) (0)
Basophil kallikrein of anaphylaxis (BK-A)--purification and characterization. (1979) (0)
656 Unique phenotypic characteristics of human uterine mast cells (UMC) (1991) (0)
Corrections - Protein Allergens of White-Faced Hornet, and Yellow Hornet, and Yellow Jacket Venom (1979) (0)
Lipid Mediators of the Allergic Reaction (Part 2 of 2) (1990) (0)
Immunotherapy for allergic disease: a four-decade investigation (2004) (0)
Antigen Jacket and Paper Wasp Venom Allergen of the Natural Allergens: Hybrids of Yellow Allergenicity but Retaining Immunogenicity Recombinant Allergens with Reduced (2001) (0)
Preliminary Observations on the Mechanism of Nasal Priming (1988) (0)
Contents, Vol. 113, 1997 (1997) (0)
In Honour of Paul Kallós (1987) (0)
The allergic state and the state of allergy. (1970) (0)
Session 2. Genetic factors and immune tolerance in allergic disorders (2004) (0)
From Molecular Science to the Treatment of Allergy (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence M. Lichtenstein?

Lawrence M. Lichtenstein is affiliated with the following schools:

Johns Hopkins University

Lawrence M. Lichtenstein's Academic­Influence.com Rankings

Lawrence M. Lichtenstein's Degrees

Why Is Lawrence M. Lichtenstein Influential?

Lawrence M. Lichtenstein's Published Works

Published Works

What Schools Are Affiliated With Lawrence M. Lichtenstein?

Lawrence M. Lichtenstein's AcademicInfluence.com Rankings